Another IL-1 blocker, canakinumab (Novartis, Basel, Switzerland) a human anti-IL-1β monoclonal antibody currently in use for the treatment of different autoimmune disorders, is also tested in COVID-19-associated lung failures in five active studies according to clinicaltrials.gov [62]. Here, IL1B is linked to COVID-19.